Drug intelligence / Profile preview

LopiGLIK

Development stage: Unknown
Lead developer: Akademy Pharma
Administration: Oral

Overview

LopiGLIK (AKP01) is a nutraceutical formulation developed by Akademy Pharma, a subsidiary of Damor Farmaceutici, for the management of cardiovascular metabolic syndrome and metabolism disorders. It is a dietary supplement containing extracts of *Berberis aristata* (standardized for berberine) and *Morus alba* (white mulberry). The product is designed to help correct cardiovascular risk factors by supporting regular cardiovascular function and regulating carbohydrate metabolism. It is typically administered orally in tablet form as part of a controlled diet to manage metabolic imbalances.

Brand names: LopiGLIK

Beyond the preview

Go deeper on LopiGLIK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LopiGLIK.

Explore the full profile